biOasis Technologies Ord Shs V.BTI.H

RE:RE:RE:RE:RE:Denali Hunter Data

[JDavenport]

Do you really think that Fabry isn't already part of the Chiesi/Bioasis deal, pof? I certainly think so, especially given the dosing timelines and half-life attributes of PRX-102.I think that PRX-102 is abolutely the best bet for a Chiesi xB3 payload. 

And then, you've got to consioder that Chiesi paid Bioasis USD $3 million up front for the four LSDs, and that's only USD $750,000 each, including for Fabry disease. The milestone payments for the 4 LSDs total USD $138 million, or $34.5 million each, including, again, for Fabry disease.

Most of those milestones will likely be payable upon commercialization of the drugs, or years from now. I understand and was encouraged that Chiesi and Bioasis described the milestones as being developmental, regulatory and commercial, but after two years and no developmental milestones we've got to consider that the bulk of the payements are years away, as royalty payments most certainly are.

The Chiesi deal is baked into this cake. Bioasis needs money and milestone payments would be welcome, but hardly a big influence on Bioasis's future or its share price. The biggest influence could be success in clinical trials with xB3-Enzymes but that still appears to be a long way off, even if Chiesi gets something into Phase 1 in the next year.

I'm not trying to be negative here. It's just that pumping Bioasis with the Chiesi deal is not very wise. The market has priced Bioasis as low as 13¢ with that deal being part of the valuation.

Bigger deals are needed and expected from Bioasis.

jd